provectus_logo.jpg
Provectus Biopharmaceuticals Announces Acceptances of PV-10 Poster Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
17. April 2019 16:05 ET | Provectus Biopharmaceuticals Inc.
Metastatic neuroendocrine tumors; Advanced cutaneous melanomaIntratumoral administration of PV-10 to visceral and superficial disease locationsSingle-agent and combination therapy treatment settings ...